NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis $16.10 +0.78 (+5.09%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mineralys Therapeutics Stock (NASDAQ:MLYS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mineralys Therapeutics alerts:Sign Up Key Stats Today's Range$15.09▼$16.7850-Day Range$11.77▼$16.8752-Week Range$8.24▼$18.38Volume2.21 million shsAverage Volume476,066 shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$38.00Consensus RatingBuy Company OverviewMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More… Mineralys Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreMLYS MarketRank™: Mineralys Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 497th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Mineralys Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.91% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.91% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.83 News SentimentMineralys Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Mineralys Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought 1,568.46% more of their company's stock than they have sold. Specifically, they have bought $25,599,996.00 in company stock and sold $1,534,353.00 in company stock.Percentage Held by Insiders25.56% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Stock News HeadlinesDavid Malcom Rodman Sells 11,366 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMay 16, 2025 | insidertrades.comMineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular ProtectionMay 20 at 8:00 AM | globenewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 21, 2025 | Golden Portfolio (Ad)What is HC Wainwright's Estimate for MLYS Q2 Earnings?May 17, 2025 | americanbankingnews.comMineralys at BofA Securities 2025: Lorundrostat’s Hypertension PromiseMay 16, 2025 | investing.comEarnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock risesMay 14, 2025 | uk.investing.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comPositive Buy Rating for Lorundrostat Driven by Successful Trials and Future PotentialMay 13, 2025 | tipranks.comSee More Headlines MLYS Stock Analysis - Frequently Asked Questions How have MLYS shares performed this year? Mineralys Therapeutics' stock was trading at $12.31 at the start of the year. Since then, MLYS stock has increased by 30.8% and is now trading at $16.10. View the best growth stocks for 2025 here. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23. Read the conference call transcript. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' top institutional shareholders include RA Capital Management L.P. (9.48%), SR One Capital Management LP (4.82%), Vanguard Group Inc. (3.14%) and Jennison Associates LLC (3.05%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mineralys Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/12/2025Today5/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLYS CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$48.00 Low Stock Price Target$24.00 Potential Upside/Downside+136.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-177,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.97% Return on Assets-62.40% Debt Debt-to-Equity RatioN/A Current Ratio14.02 Quick Ratio14.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.84 per share Price / Book4.19Miscellaneous Outstanding Shares65,175,000Free Float33,271,000Market Cap$1.05 billion OptionableOptionable Beta-0.30 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:MLYS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.